Gri Bio Inc (GRI)

$2.94 +0.19 (6.91%)
Market Cap 3.61M
Revenue (ttm) 0.00
Net Income (ttm) -11.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 88,518
Avg Vol 473,387
Day's Range N/A - N/A
Shares Out 1.45M
Stochastic %K 100%
Beta -1.38
Analysts Sell
Price Target $509.20

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 400 1170
Address:
2223 Avenida de la Playa, Suite 208, La Jolla, United States
No_Face_character
No_Face_character Mar. 11 at 2:42 PM
$GRI watching
0 · Reply
StocktwitsAragorn
StocktwitsAragorn Mar. 11 at 2:28 PM
$GRI https://www.stockscores.com/charts/charts/?ticker=gri Huge open gap to fill at much higher prices!
1 · Reply
AZOZ
AZOZ Mar. 11 at 2:07 PM
$GRI Reversal in progress!
0 · Reply
anachartanalyst
anachartanalyst Mar. 11 at 1:02 PM
$GRI https://anachart.com/wp-content/uploads/ana_temp/1773234080_soc-img.jpg
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 11 at 12:48 PM
$GRI Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40
0 · Reply
Zackpedia
Zackpedia Mar. 11 at 10:00 AM
$GRI 2.76 resistance! You know what to do
0 · Reply
AZOZ
AZOZ Mar. 10 at 5:03 PM
$GRI On watch for upside continuation!
0 · Reply
dButterz
dButterz Mar. 6 at 4:48 PM
$GRI dont clap dont clap
0 · Reply
dButterz
dButterz Mar. 6 at 1:22 PM
$GRI despicable 🤬🤬🤬🤬
1 · Reply
Reaganomics_Lamborghini
Reaganomics_Lamborghini Mar. 4 at 2:55 PM
$GRI let’s go you turd
0 · Reply
Latest News on GRI
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Feb 17, 2026, 9:15 AM EST - 22 days ago

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 4 weeks ago

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Feb 4, 2026, 8:45 AM EST - 5 weeks ago

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Jan 28, 2026, 8:45 AM EST - 6 weeks ago

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Reverse Stock Split

Jan 21, 2026, 4:01 PM EST - 7 weeks ago

GRI Bio Announces Reverse Stock Split

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 12, 2025, 4:05 PM EST - 3 months ago

GRI Bio Announces Closing of $8.0 Million Public Offering

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 11, 2025, 9:15 AM EST - 3 months ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Dec 10, 2025, 4:05 PM EST - 3 months ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 6 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 7 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 31, 2025, 1:50 PM EDT - 7 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 8 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jul 1, 2025, 8:45 AM EDT - 9 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 9 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 21, 2025, 9:15 AM EDT - 10 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 16, 2025, 9:15 AM EDT - 10 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:35 AM EDT - 10 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 8, 2025, 8:45 AM EDT - 10 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 11 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 16, 2025, 8:35 AM EDT - 11 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 2, 2025, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 1 year ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Apr 1, 2025, 11:07 AM EDT - 1 year ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 31, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 18, 2025, 9:05 AM EDT - 1 year ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 17, 2025, 8:05 AM EDT - 1 year ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Mar 11, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

No_Face_character
No_Face_character Mar. 11 at 2:42 PM
$GRI watching
0 · Reply
StocktwitsAragorn
StocktwitsAragorn Mar. 11 at 2:28 PM
$GRI https://www.stockscores.com/charts/charts/?ticker=gri Huge open gap to fill at much higher prices!
1 · Reply
AZOZ
AZOZ Mar. 11 at 2:07 PM
$GRI Reversal in progress!
0 · Reply
anachartanalyst
anachartanalyst Mar. 11 at 1:02 PM
$GRI https://anachart.com/wp-content/uploads/ana_temp/1773234080_soc-img.jpg
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 11 at 12:48 PM
$GRI Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40
0 · Reply
Zackpedia
Zackpedia Mar. 11 at 10:00 AM
$GRI 2.76 resistance! You know what to do
0 · Reply
AZOZ
AZOZ Mar. 10 at 5:03 PM
$GRI On watch for upside continuation!
0 · Reply
dButterz
dButterz Mar. 6 at 4:48 PM
$GRI dont clap dont clap
0 · Reply
dButterz
dButterz Mar. 6 at 1:22 PM
$GRI despicable 🤬🤬🤬🤬
1 · Reply
Reaganomics_Lamborghini
Reaganomics_Lamborghini Mar. 4 at 2:55 PM
$GRI let’s go you turd
0 · Reply
Zackpedia
Zackpedia Mar. 3 at 2:07 PM
$GRI You could’ve sold above 1.5
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 27 at 7:05 PM
$NVTS i want $9 $GRI i want $3
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 27 at 1:59 AM
$GRI i want $72
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 23 at 3:54 PM
$GRI what the hell 10% down? Are they selling more ATM
0 · Reply
gregwiseman
gregwiseman Feb. 23 at 9:45 AM
$GRI 0.2
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 23 at 7:56 AM
$GRI They are planning to sell $250M worth of atm. Lets see how this plays out. They don't have cash to start phase 2b/3
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 20 at 5:28 PM
$GRI from member of comment committee This is pos
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 19 at 4:00 PM
$GRI i want $3
1 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 19 at 3:19 PM
$GRI $250 million ATM to be sold Wow thats alot of dilution!
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 19 at 3:01 PM
$GRI they are known to use good news to offload ATM
0 · Reply
Cocky_day_trader
Cocky_day_trader Feb. 19 at 3:00 PM
$GRI yet they dont have sufficient cash yo run next phase. Only cash is operational and pay themselves
0 · Reply
zigsfrd
zigsfrd Feb. 19 at 2:54 PM
$GRI Look at the latest Nobel Prize winners in the T cell arena. Extremely positive for our company and our approach. Great news.
0 · Reply